Country for PR: Japan
Contributor: Kyodo News JBN
Wednesday, February 16 2022 - 17:00
NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody
OSAKA, Japan, Feb. 16, 2022 /Kyodo JBN-AsiaNet/ --

- Potential Candidate as Broad-spectrum Therapeutic Agent for Coronavirus 
Diseases Caused by Different Coronaviruses, including Variants -

The National Institutes of Biomedical Innovation, Health and Nutrition 
(NIBIOHN; Ibaraki-shi, Osaka; Director-general: Yoshihiro Yoneda), in 
partnership with Shionogi & Co., Ltd. (Chuo-ku, Osaka; President and CEO: Isao 
Teshirogi), has successfully identified a novel antiviral antibody for severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its variants, and 
closely associated coronavirus species.



The newly identified antibody binds to virus spike proteins displayed on the 
infected cell surface. The bound antibody supports the immune response of 
infected individuals to attack the infected cells via antibody-dependent 
cell-mediated cytotoxicity (ADCC). Unlike many other antibody drugs, the newly 
identified antibody's binding site (epitope) resides in a specific part of the 
spike structure poorly susceptible to mutation. Therefore, the antibody reacts 
with various virus variants, including the Omicron variant. Moreover, because 
the epitope structure with few mutations is common among many other related 
coronaviruses, the newly identified antiviral antibody is expected to show 
efficacy against a broad spectrum of coronaviruses, including potential 
variants in the future.

In current clinical use, antibody cocktails and other neutralizing antibodies 
target individuals with mild infection. In contrast, the newly identified 
antibody may be suitable to treat patients at high risk of disease of greater 
severity. In addition, a "broad-spectrum antiviral antibody" should be ideal 
for emergency use in the event of a probable new coronavirus pandemic in the 
future. NIBIOHN will conduct further research.

For research details, please visit:

Source: National Institutes of Biomedical Innovation, Health and Nutrition